Evidence map›Paper›PMID 42897686›Full record

ArticleCardio-oncology (London, England)2026

Performance status and outcomes in patients with cancer receiving thromboprophylaxis: a subanalysis of the AVERT trial.

Nicola Potere, Yan Xu, Ranjeeta Mallick, Tzu-Fei Wang, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Sudeep Shivakumar, Marcello Di Nisio, Philip S Wells and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicola PotereDepartment of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Yan XuDepartment of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Ranjeeta MallickOttawa Methods Center, Ottawa Ottawa Hospital Research Institute, Ottawa, ON, Canada.
Tzu-Fei WangDepartment of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Danny HillSault Area Hospital, Sault Ste. Marie, Canada.
Alejandro Lazo-LangnerLondon Health Sciences Centre, London, Canada.
Vicky TagalakisLady Davis Institute for Medical Research, Jewish General Hospital, McGill University, Montreal, Canada.
Sudeep ShivakumarDepartment of Medicine, Nova Scotia Health, Dalhousie University, Halifax, NS, Canada.
Marcello Di NisioDepartment of Medicine and Ageing Sciences, Gabriele D'Annunzio University, Chieti, Italy.
Philip S WellsDepartment of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada.
Marc CarrierDepartment of Medicine, The Ottawa Hospital and Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada. mcarrier@toh.ca.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Eastern Cooperative Oncology Group Performance Status (ECOG-PS) is central to cancer care planning and prognostication. Whether ECOG-PS also carries prognostic value in the setting of primary thromboprophylaxis for cancer-associated venous thromboembolism (VTE) remains unknown.

objectivesTo evaluate the impact of ECOG-PS on clinical outcomes in ambulatory patients with cancer initiating chemotherapy.

methodsThis was a post-hoc analysis of the AVERT randomized controlled trial that evaluated apixaban (2.5 mg twice daily) for thromboprophylaxis in patients at intermediate-to-high VTE risk. Multivariable survival models assessed the association between ECOG-PS (0-1 versus 2-3) and the composite primary outcome of VTE or clinically relevant bleeding (CRB), as well as its individual components and all-cause mortality, over 180 days.

resultsOf 428 patients included, 368 (86.0%) and 60 (14.0%) had an ECOG-PS of 0-1 and 2-3, respectively. The primary composite outcome occurred in 12.8% (n = 47) in those with ECOG 0-1 and 18.3% (n = 11) with ECOG-PS 2-3 (6-month cumulative incidence: 13.0% [95% CI: 9.8%-16.7%] versus 19.9% [95% CI: 10.5%-31.4%], respectively). Worse performance status was associated with higher risks for the composite outcome (aHR: 1.76; 95% CI: 1.14-2.72; p = 0.011), CRB (aHR: 1.58; 95%CI: 1.53-1.63; p < 0.0001), and all-cause mortality (aHR: 5.77; 95% CI: 4.98-6.67; p < 0.0001). In exploratory treatment-effect analyses, apixaban reduced VTE risk across ECOG-PS strata, including among participants with ECOG-PS 2-3, without clear evidence of excess CRB in this subgroup.

conclusionsECOG-PS predicts VTE-related outcomes in ambulatory patients with cancer and may inform individualized, value-based shared decision-making regarding anticoagulant thromboprophylaxis.

Indexed as

AnticoagulationApixabanCardio-oncologyDeep vein thrombosisFrailtyPerformance statusPulmonary embolismThromboprophylaxis

Identifiers

PMID42897686
PMCPMC13679223

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.